COMT Val158Met modulates subjective responses to intravenous nicotine and cognitive performance in abstinent smokers

Pharmacogenomics Journal

Volumn 13, Issue 6, 2013, Pages 490-497

  Herman, A I ^a   Jatlow, P I ^a   Gelernter, J ^a   Listman, J B ^a   Sofuoglu, M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cigarette; COMT; genetics; nicotine; pharmacogenetic; smoking

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE; NICOTINE TARTRATE; SODIUM CHLORIDE; VALINE;

ADULT; AFRICAN AMERICAN; ARTICLE; COGNITION; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MENTAL PERFORMANCE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

CATECHOL O-METHYLTRANSFERASE; COGNITION; HUMANS; INFUSIONS, INTRAVENOUS; METHIONINE; NICOTINE; SMOKING; SUBSTANCE WITHDRAWAL SYNDROME; VALINE;

EID: 84888133878     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.1     Document Type: Article

References (68)

1. Slifstein M, Kolachana B, Simpson EH, Tabares P, Cheng B, Duvall M et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry 2008; 13: 821-827.
2. Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 1958; 233: 702-705.
3. Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev 1966; 18: 95-113.
4. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-250.
5. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19-52.
6. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-6922.
7. Opmeer EM, Kortekaas R, Aleman A. Depression and the role of genes involved in dopamine metabolism and signalling. Prog Neurobiol 2010; 92: 112-133.
8. Costas J, Sanjuan J, Ramos-Rios R, Paz E, Agra S, Ivorra JL et al. Heterozygosity at catechol-O-methyltransferase Val158Met and schizophrenia: new data and metaanalysis. J Psychiatr Res 2011; 45: 7-14.
9. Tammimaki AE, Mannisto PT. Are genetic variants of COMT associated with addiction? Pharmacogenet Genomics 2010; 20: 717-741.
10. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006; 29: 565-598.
11. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J et al. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 2005; 15: 393-398.
12. Munafo MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet Genomics 2008; 18: 121-128.
13. Omidvar M, Stolk L, Uitterlinden AG, Hofman A, Van Duijn CM, Tiemeier H. The effect of catechol-O-methyltransferase Met/Val functional polymorphism on smoking cessation: retrospective and prospective analyses in a cohort study. Pharmacogenet Genomics 2009; 19: 45-51.
14. David SP, Munafo MR. Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics 2008; 9: 1307-1321.
15. McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 2000; 10: 483-491.
16. Loughead J, Wileyto EP, Valdez JN, Sanborn P, Tang K, Strasser AA et al. Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol Psychiatry 2009; 14: 820-826.
17. Wang Z, Ray R, Faith M, Tang K, Wileyto EP, Detre JA et al. Nicotine abstinenceinduced cerebral blood flow changes by genotype. Neurosci Lett 2008; 438: 275-280.
18. Egan MF, Hyde TM, Bonomo JB, Mattay VS, Bigelow LB, Goldberg TE et al. Relative risk of neurological signs in siblings of patients with schizophrenia. Am J Psychiatry 2001; 158: 1827-1834.
19. Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci USA 2009; 106: 617-622.
20. Wichers M, Aguilera M, Kenis G, Krabbendam L, Myin-Germeys I, Jacobs N et al. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. Neuropsychopharmacology 2008; 33: 3030-3036.
21. Htun NC, Miyaki K, Song Y, Ikeda S, Shimbo T, Muramatsu M. Association of the catechol-O-methyl transferase gene Val158Met polymorphism with blood pressure and prevalence of hypertension: interaction with dietary energy intake. Am J Hypertens 2011; 24: 1022-1026.
22. Sofuoglu M, Yoo S, Hill KP, Mooney M. Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology 2008; 33: 715-720.
23. Sofuoglu M, Herman AI, Nadim H, Jatlow P. Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology 2012; 37: 1509-1516.
24. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSMIV Axis I Disorders-Patient Edition (SCID-I/P, Version 2. 0). Biometrics Research Department, New York State Psychiatric Institute: New York, NY, USA, 1995.
25. Sofuoglu M, Mouratidis M, Yoo S, Culligan K, Kosten T. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2005; 181: 504-510.
26. Sofuoglu M, Poling J, Mouratidis M, Kosten T. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2006; 184: 645-651.
27. Sofuoglu M, Waters AJ, Mooney M, O'Malley SS. Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans. Pharmacol Biochem Behav 2009; 92: 135-140.
28. Benowitz NL, Jacob III P, Abijevych KL, Jarvis MJ, Hall S, LeHouezec J et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002; 4: 149-159.
29. al'Absi M, Amunrud T, Wittmers LE. Psychophysiological effects of nicotine abstinence and behavioral challenges in habitual smokers. Pharmacol Biochem Behav 2002; 72: 707-716.
30. Mendelson JH, Sholar MB, Goletiani N, Siegel AJ, Mello NK. Effects of low-and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology 2005; 30: 1751-1763.
31. Newhouse PA, Sunderland T, Narang PK, Mellow AM, Fertig JB, Lawlor BA et al. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease. Psychoneuroendocrinology 1990; 15: 471-484.
32. Pickworth WB, Fant RV. Endocrine effects of nicotine administration, tobacco and other drug withdrawal in humans. Psychoneuroendocrinology 1998; 23: 131-141.
33. Alexander N, Osinsky R, Mueller E, Schmitz A, Guenthert S, Kuepper Y et al. Genetic variants within the dopaminergic system interact to modulate endocrine stress reactivity and recovery. Behav Brain Res 2011; 216: 53-58.
34. Wolff K, Tsapakis EM, Pariante CM, Kerwin RW, Forsling ML, Aitchison KJ. Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. Journal of psychopharmacology (Oxford, England) 2012; 26: 419-428.
35. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict 1991; 86: 1467-1476.
36. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tobacco Res 2001; 3: 7-16.
37. Bell SL, Taylor RC, Singleton EG, Henningfield JE, Heishman SJ. Smoking after nicotine deprivation enhances cognitive performance and decreases tobacco craving in drug abusers. Nicotine Tobacco Res 1999; 1: 45-52.
38. Morgan MJ, Davies GM, Willner P. The questionnaire of smoking urges is sensitive to abstinence and exposure to smoking-related cues. Behav Pharmacol 1999; 10: 619-626.
39. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43: 289-294.
40. Hughes JR, Hatsukami DK. Effects of three doses of transdermal nicotine on postcessation eating, hunger and weight. J Subst Abuse 1997; 9: 151-159.
41. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988; 54: 1063-1070.
42. Reeves D, Kane R, Winter K. Automated Neuropsychological Assessment Metrics (ANAM v3. 11a/96) User's Manual: Clinical and Neurotoxicology Subset. National Cognitive Foundation: San Deigo, CA, USA, 1996, NCRF-SR 96-01.
43. Snyder FR, Henningfield JE. Effects of nicotine administration following 12 h of tobacco deprivation: assessment on computerized performance tasks. Psychopharmacology (Berl) 1989; 97: 17-22.
44. Mancuso G, Warburton DM, Melen M, Sherwood N, Tirelli E. Selective effects of nicotine on attentional processes. Psychopharmacology (Berl) 1999; 146: 199-204.
45. Mancuso G, Andres P, Ansseau M, Tirelli E. Effects of nicotine administered via a transdermal delivery system on vigilance: a repeated measure study. Psychopharmacology (Berl) 1999; 142: 18-23.
46. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. Spreen O, Strauss E (eds. ) Oxford University Press: New York, NY, USA, 1991.
47. Sofuoglu M, Herman AI, Nadim H, Jatlow P. Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology 2012; 37: 1509-1516.
48. Dempsey D, Tutka P, Jacob 3rd P, Allen F, Schoedel K, Tyndale RF et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 2004; 76: 64-72.
49. Guo S, Chen da F, Zhou DF, Sun HQ, Wu GY, Haile CN et al. Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers. Psychopharmacology (Berl) 2007; 190: 449-456.
50. Benowitz NL, Hukkanen J, Jacob 3rd P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009; 192: 29-60.
51. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
52. Yang BZ, Zhao H, Kranzler HR, Gelernter J. Characterization of a likelihood based method and effects of markers informativeness in evaluation of admixture and population group assignment. BMC Genet 2005; 6: 50.
53. Domschke K, Baune BT, Havlik L, Stuhrmann A, Suslow T, Kugel H et al. Catechol-O-methyltransferase gene variation: impact on amygdala response to aversive stimuli. Neuroimage 2012; 60: 2222-2229.
54. Witte AV, Floel A. Effects of COMT polymorphisms on brain function and behavior in health and disease. Brain Res Bull 2012; 88: 418-428.
55. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O- methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004; 29: 1943-1961.
56. Zhang L, Dong Y, Doyon WM, Dani JA. Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens. Biol Psychiatry 2012; 71: 184-191.
57. Stewart SH, Oroszi G, Randall PK, Anton RF. COMT genotype influences the effect of alcohol on blood pressure: results from the COMBINE study. Am J Hypertens 2009; 22: 87-91.
58. Hagen K, Pettersen E, Stovner LJ, Skorpen F, Holmen J, Zwart JA. High systolic blood pressure is associated with Val/Val genotype in the catechol-o-methyltransferase gene. The Nord-Trondelag Health Study (HUNT). Am J Hypertens 2007; 20: 21-26.
59. Grim CE, Luft FC, Miller JZ, Meneely GR, Battarbee HD, Hames CG et al. Racial differences in blood pressure in Evans County, Georgia: relationship to sodium and potassium intake and plasma renin activity. J Chronic Dis 1980; 33: 87-94.
60. Chrysant SG, Danisa K, Kem DC, Dillard BL, Smith WJ, Frohlich ED. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension 1979; 1: 136-141.
61. Luft FC, Grim CE, Higgins Jr. JT, Weinberger MH. Differences in response to sodium administration in normotensive white and black subjects. J Lab Clin Med 1977; 90: 555-562.
62. Armani C, Landini Jr. L, Leone A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr Pharm Des 2009; 15: 1038-1053.
63. Tunbridge EM, Harrison PJ. Importance of the COMT gene for sex differences in brain function and predisposition to psychiatric disorders. Curr Topics Behav Neurosci 2011; 8: 119-140.
64. Olsson CA, Anney RJ, Lotfi-Miri M, Byrnes GB, Williamson R, Patton GC. Association between the COMT Val158Met polymorphism and propensity to anxiety in an Australian population-based longitudinal study of adolescent health. Psychiatr Genet 2005; 15: 109-115.
65. Sofuoglu M, Lesage MG. The reinforcement threshold for nicotine as a target for tobacco control. Drug Alcohol Depend 2012; 125: 1-7.
66. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007; 32: 1011-1020.
67. Roussos P, Giakoumaki SG, Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol Psychiatry 2009; 66: 997-1004.
68. Shafa R. COMT-inhibitors may be a promising tool in treatment of marijuana addiction trials. A J Addict 2009; 18: 322.